Liquidia (NASDAQ:LQDA) General Counsel Sells $1,021,427.27 in Stock

Liquidia Corporation (NASDAQ:LQDA) General Counsel Russell Schundler sold 27,289 shares of the stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $37.43, for a total transaction of $1,021,427.27. Following the completion of the transaction, the general counsel directly owned 579,394 shares of the company’s stock, valued at approximately $21,686,717.42. The trade was a 4.50% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Russell Schundler also recently made the following trade(s):

• On Monday, December 1st, Russell Schundler sold 1,072 shares of Liquidia stock. The stock was sold at an average price of $32.19, for a total transaction of $34,507.68.

Liquidia Price Performance

Shares of NASDAQ:LQDA traded up $1.49 during trading on Tuesday, hitting $38.09. 2,055,159 shares of the company were exchanged, compared to its average volume of 2,814,845. Liquidia Corporation has a 1-year low of $11.26 and a 1-year high of $39.29. The company has a market capitalization of $3.31 billion, a P/E ratio of -26.45, a price-to-earnings-growth ratio of 1.19 and a beta of 0.48. The company has a quick ratio of 1.96, a current ratio of 2.20 and a debt-to-equity ratio of 6.19. The business’s 50 day moving average is $31.94 and its 200-day moving average is $25.40.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings data on Monday, November 3rd. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.41. Liquidia had a negative return on equity of 296.78% and a negative net margin of 176.04%.The business had revenue of $54.34 million for the quarter, compared to analyst estimates of $18.86 million. The business’s quarterly revenue was up 1106.7% compared to the same quarter last year. Equities analysts forecast that Liquidia Corporation will post -1.51 earnings per share for the current year.

Analyst Ratings Changes

LQDA has been the topic of several recent research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Liquidia in a research report on Wednesday, October 8th. BTIG Research reiterated a “buy” rating and set a $49.00 price target on shares of Liquidia in a report on Friday. Wall Street Zen upgraded Liquidia from a “hold” rating to a “buy” rating in a report on Saturday. HC Wainwright raised their target price on Liquidia from $35.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. Finally, Raymond James Financial reissued a “strong-buy” rating and issued a $47.00 price target on shares of Liquidia in a research note on Tuesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $39.67.

Institutional Trading of Liquidia

A number of large investors have recently bought and sold shares of LQDA. NewEdge Advisors LLC acquired a new position in shares of Liquidia in the 2nd quarter valued at about $25,000. Skandinaviska Enskilda Banken AB publ acquired a new stake in Liquidia during the third quarter worth approximately $30,000. FNY Investment Advisers LLC bought a new stake in Liquidia in the third quarter worth approximately $34,000. Steward Partners Investment Advisory LLC lifted its stake in Liquidia by 24.0% in the second quarter. Steward Partners Investment Advisory LLC now owns 6,200 shares of the company’s stock valued at $77,000 after buying an additional 1,200 shares during the period. Finally, Tower Research Capital LLC TRC lifted its stake in Liquidia by 281.2% in the second quarter. Tower Research Capital LLC TRC now owns 6,679 shares of the company’s stock valued at $83,000 after buying an additional 4,927 shares during the period. 64.54% of the stock is currently owned by institutional investors and hedge funds.

Key Liquidia News

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Short interest fell materially in December — short interest declined 18.1% to 10,709,682 shares as of Dec. 31 (about 17.6% of shares were sold short) and the days-to-cover was ~11.6. Fewer active shorts can reduce downside pressure and may have contributed to the stock moving higher. (Market data entry)
• Neutral Sentiment: January short-interest data shows 0 shares as of Jan. 12 — this is almost certainly a reporting or data glitch rather than a real liquidation of all short positions. Investors should monitor the next short-interest report for a corrected figure. (Market data entry)
• Negative Sentiment: CEO Roger Jeffs sold 66,610 shares at an average $37.43 (≈$2.49M); his stake decreased ~6.03%. This large insider sale may be seen as a negative signal by some investors. SEC Filing
• Negative Sentiment: CFO Michael Kaseta sold 36,932 shares at $37.43 (≈$1.38M); his holding fell ~9.52%. SEC Filing
• Negative Sentiment: General Counsel Russell Schundler sold 27,289 shares at $37.43 (≈$1.02M); his holding fell ~4.50%. SEC Filing
• Negative Sentiment: Other insiders (including Rajeev Saggar, Jason Adair, Scott Moomaw, Sarah Krepp, CAO Dana Boyle) also executed sales on Jan. 12 at ~$37.43 per share, each reducing positions between ~6–11.7%. These combined sales represent significant insider liquidity taken at current prices. Rajeev Saggar SEC Filing Dana Boyle SEC Filing Jason Adair SEC Filing Scott Moomaw SEC Filing Sarah Krepp SEC Filing

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).